Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants

Pediatrics. 2007 Jul;120(1):40-8. doi: 10.1542/peds.2006-3158.

Abstract

Background: Low cortisol concentrations in premature infants have been correlated with increased severity of illness, hypotension, mortality, and development of bronchopulmonary dysplasia. A total of 360 mechanically ventilated infants with a birth weight of 500 to 999 g were enrolled in a randomized, multicenter trial of prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia. Mortality and bronchopulmonary dysplasia were decreased in the hydrocortisone-treated patients exposed to chorioamnionitis. We now report outcomes at 18 to 22 months' corrected age.

Patients and methods: Surviving infants were evaluated with standardized neurologic examination and Bayley Scales of Infant Development-II. Neurodevelopmental impairment was defined as a Mental Developmental Index or Psychomotor Developmental Index of <70, cerebral palsy, blindness or deafness.

Results: A total of 252 (87%) of 291 survivors were evaluated. Cerebral palsy was diagnosed in 13% of hydrocortisone-treated versus 14% of placebo-treated infants. Fewer hydrocortisone-treated infants had a Mental Development Index <70, and more of the hydrocortisone-treated infants showed evidence of awareness of object permanence. Incidence of neurodevelopmental impairment was not different (39% [hydrocortisone] vs 44% [placebo]). There were no differences in physical growth measures. Chorioamnionitis-exposed infants treated with hydrocortisone were shorter and weighed less than controls but had no evidence of neurodevelopmental impairment. Among infants not exposed to chorioamnionitis, hydrocortisone-treated patients were less likely to have a Mental Development Index of <70 or to be receiving glucocorticoids at follow-up.

Conclusions: Early, low-dose hydrocortisone treatment was not associated with increased cerebral palsy. Treated infants had indicators of improved developmental outcome. Together with the short-term benefit previously reported, these data support additional studies of hydrocortisone treatment of adrenal insufficiency in extremely premature infants.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adrenal Insufficiency / prevention & control
  • Bronchopulmonary Dysplasia / mortality
  • Bronchopulmonary Dysplasia / therapy
  • Cerebral Palsy / prevention & control
  • Child Development*
  • Chorioamnionitis / blood
  • Developmental Disabilities / prevention & control*
  • Dexamethasone / administration & dosage
  • Dexamethasone / adverse effects
  • Female
  • Humans
  • Hydrocortisone / administration & dosage
  • Hydrocortisone / adverse effects
  • Hydrocortisone / analogs & derivatives*
  • Hydrocortisone / blood
  • Infant
  • Infant, Extremely Low Birth Weight / growth & development*
  • Infant, Newborn
  • Intestinal Perforation / chemically induced
  • Male
  • Neurologic Examination
  • Pregnancy
  • Psychomotor Disorders / prevention & control
  • Respiration, Artificial
  • Survival Rate

Substances

  • Dexamethasone
  • hydrocortisone hemisuccinate
  • Hydrocortisone